Advanced search
Start date

Assessment of Inflammation in the early and late stage of Bipolar Disorder

Grant number: 18/02910-8
Support type:Regular Research Grants
Duration: August 01, 2018 - July 31, 2020
Field of knowledge:Health Sciences - Medicine - Psychiatry
Principal Investigator:Alexandre Duarte Gigante
Grantee:Alexandre Duarte Gigante
Home Institution: Faculdade de Medicina Dr Domingos Leonardo Ceravolo. Universidade do Oeste Paulista (UNOESTE). Campus de Presidente Prudente. Presidente Prudente , SP, Brazil
Assoc. researchers:Eliana Peresi Lordelo ; Gilmara Peixoto Rister ; Márjorie de Assis Golim


Bipolar disorder (BD) is a serious mental disorder characterized by mood swings, circadian rhythm disturbances and constant fluctuations in energy, affect, sleep, and cognition levels. The disease is chronic, recurrent and of varying duration, usually onset in young adults, and may begin in individuals in later age groups. The BD has great morbidity, mortality and socioeconomic impact, since it is associated with high rates of recurrence, incomplete remission and partial recovery between episodes. Several studies show the damage of the disease in the plasticity and neuronal survival and its influence on the action of neurotransmitters, hormones, neurotrophins and inflammatory mediators. It is intended to study the presence of inflammatory biomarkers at the onset of the disease, after many years of illness and in healthy controls. Structured interviews and blood samples were collected to identify biochemical alterations suggestive of inflammatory activity. C Reactive Protein, Hemosideration Rate, Alpha-1 Acid Glycoprotein, Protein Electrophoresis, Interleukin 2, Interleukin 6, Interleukin 4, Interleukin 10 and Tumor Necrosis Factor-alpha patient groups and controls. The association between inflammatory cytokines and disease time may contribute to a therapeutic approach that focuses on preventive aspects of BD neuroprogression, collaborating in the search for an understanding of neurobiology and the discovery of biomarkers that may lead to the development of new treatment strategies and better prognosis for patients. (AU)